Dengue is a highly prevalent mosquito-borne disease that is endemic in over 100 countries. It has a wider impact in terms of severity of illness and mortality risk in the absence of an effective vaccine as yet. The purpose of this study was to use meta-analysis to find out how common the dengue virus (DENV) is in India based on public data and to figure out how much of a problem. We searched, read, and reviewed about DENV in India that were available online. Forty-four cross-sectional studies were selected from the 178 records. There were reports of dengue cases in 14 out of the 28 states. Out of the patients presenting with symptoms of Dengue 27% of people were confirmed to have DENV infection with 82.29% (95% CI. 81-84%), having dengue IgM, 41.67% (95% CI: 40.16-43.43), having dengue IgG, and 23.97% (95% C.I. 14-43%), having both IgG and IgM from positive sample n=27156. Hospital-based cross-sectional studies on suspected Dengue-like illness (DLI) found that 99.48% of people had confirmed dengue out of the patients with features of DLI, and community-based studies found that 0.52% of DLI cases had dengue. The seroprevalence rates for East, South, North, and Western regions were 35.38% (95% C.I.14-31%), 11.57% (95% C.I. 2-69%), 38.10% (95% C.I. 9-61%), and 14.87% (95% C.I. 6-38%) correspondingly. DENV is interestingly spreading across the whole country, and the disease’s frequency varies a lot from place to place and from 2010-2023. However this review does not find appropriate published literature from 50% of the Indian states. The identification of IgG-class antibodies to dengue virus is indicative of prior exposure to this pathogen. Almost all immunocompetent individuals should have developed IgG antibodies against the dengue virus within three weeks of exposure. The presence of dengue virus IgM-class antibodies is indicative of an acute phase of infection. National Vector borne Disease Control Programme (NVBDCP) has some surveillance information, appropriate designed research into prevalence and risk factors for DENV infection would be required to provide adequate information for public health intervention.
Genus Leuconostoc is a group of a diverse range of lactic acid bacteria (LAB) majorly found in dairy, food and environmental ecology. These microbes are commercially important for several industries due to their intrinsic genomic attributes such as bacteriocins, carbohydrate-active enzymes, plasmids etc. Even though the species of Leuconostoc are commercially significant, their taxonomy is largely based on old, low resolution traditional methods. There have been several taxonomic reclassifications in the past which are inadequate for microbiologist and food industry professionals to truly demarcate any new strain of genus Leuconostoc . The current taxonomy of the genus is largely based on classical approaches, which are in utmost need of reinvestigation by whole genome-based approaches. In the present study, the taxono-phylogenomic analysis clearly depicted sixteen species including three novel genomospecies in addition to several reshufflings across the species namely, L. mesenteroides, L. pseudomesenteroides, L. gelidum and L. lactis . The presence of a wide range of carbohydrate-active enzymes, type III polyketide synthase and vector plasmids suggested the biotechnological potential of constituent strains of the genera. Further, the absence of antibiotic gene clusters reaffirms their utility in industries such as food and dairy. Such large-scale in-depth genome-based study can shed light on the nature of the genome dynamics of the species and help to obtain a more robust taxonomic classification.
Nanotechnology has a major impact on the creation of novel and effective therapies for the treatment of several diseases, including diabetes and cancer. The current work is a report on the use of the aqueous extract from the leaves of the Flemingia macrophylla plant as a capping and reducing agent in the green synthesis of zinc oxide nanoparticles (ZnO-NPs).The synthesized ZnO-NPs were subjected to characterization through X-ray diffraction (XRD), Fourier transform infrared spectroscopy (FT-IR), transmission electron microscopy (TEM) scanning electron microscopy (SEM), and ultraviolet-visible spectroscopy (UV-Vis). Dose-dependent in vivo effects were investigated using Drosophila melanogaster subjected to a high-sugar diet (HSD) to induce a diabetic-like model. In vitro anti-oxidant, anti-diabetic, anti-inflammatory assay, survival, locomotor function, neuroanatomical integrity, ovary and testis morphology, egg-laying capacity, and male fertility were evaluated. The most prominent UV-visible peak was detected at around 370 nm. Structural and morphological analysis via XRD and electron microscopy confirmed the hexagonal phase of the ZnO-NPs, indicating an average calcined particle size of around 47 nm at 500°C.The manuscript reports significant anti-diabetic and anti-inflammatory effects in vitro and in the in vivo Drosophila model, together with antioxidant activity. The in vivo results indicate that green-synthesized ZnO-NPs mitigate adverse phenotypes triggered by a high-sugar diet and also potential as an anti-diabetic intervention and warrant further mechanistic and preclinical investigation.
L-asparaginase (EC 3.5.1.1) is an enzyme that mostly helps break down asparagine into L-aspartic acid and ammonium in water. This enzyme can be found in many living things, like bacteria, plants, and some animals, like the serum of some rodents. Especially for Acute Lymphoblastic Leukaemia (ALL) and Hodgkin’s lymphoma, it is an important chemotherapeutic drug for treating lymphoproliferative diseases and lymphomas. When L-asparaginase comes in contact with water, it breaks down more easily. At the moment, biotechnological methods using certain microorganisms are mostly used to make L-asparaginase. Still, industrial manufacturing needs a study that focuses on both increasing production yields and coming up with new ways to do things, like using different microbes to make enzymes useful in more situations. This review gives an overview of L-asparaginase’s uses and talks about how it is made by different microbes, as well as its limitations, current research, and issues that need to be fixed before it can be used in industry.